Cancer diagnostics firm Burning Rock Biotech's Q3 revenue rises on pharma R&D growth

Burning Rock Biotech

20/11/2025 08:28

Overview

Burning Rock Q3 2025 revenue rises 2.3% yr/yr, driven by pharma R&D services growth

Company reports net loss of RMB16.8 mln for Q3 2025, reduced from last year

Adjusted gross margin improves to 76.7% in Q3 2025, reflecting cost reductions

Outlook

Company did not provide specific guidance for future quarters in press release

Result Drivers

PHARMA R&D GROWTH - Revenue from pharma research and development services increased 68.6%, driven by higher demand for development and testing services

IN-HOSPITAL SHIFT - Decline in central laboratory revenue due to transition towards in-hospital testing

GROSS MARGIN IMPROVEMENT - Gross margin rose to 75.1%, aided by high-margin CDx projects and cost reductions

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
RMB 131.60 mln
Q3 Net Income
-RMB 16.80 mln
Q3 Adjusted Gross Margin
76.70%
Q3 Gross Profit
RMB 98.80 mln
Q3 Operating Expenses
RMB 115 mln


Press Release: ID:nGNX9HfyLR

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)